25 January 2024
25 January 2024
Phase II of Gate’s zelquistinel will use Becon’s Dreem 3S headband device to conduct exploratory EEG and sleep analyses in patients with major depressive disorder.
Depending on the outcome of Femasys’ FINALE pivotal trial, a non-surgical device for permanent birth control could be available again.
Initial results from the clinical trial indicate that AK-OTOF gene therapy restored hearing in patients with profound loss.
The trial will involve 128 subjects from across ten Australian trial sites.
The development follows Onward's acquisition of rights for OT-A201 from Biomunex in February 2021.
The technology is projected to aid Velocity in saving more than 650 working days.
The ongoing Phase II Ampligen trial will advance to a European site, enrolling 90 pancreatic cancer patients.
The development comes after the company raised $65m to expand clinical evidence for its neurostimulation system.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
